CALIXAR team will be present at the online BioPharm America event, from September 20 to 23, 2021 to discuss about commercial and scientific opportunities linked to our activities.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.
CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025.
About BioPharm America:
BioPharm America™ Digital creates a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions. It brings dealmakers from the life science ecosystem together to engage and reduce the enormous task of drug development.
For more information and meet us: BioPharm America